Skip to main content
Eutilex Co.,Ltd. logo

Eutilex Co.,Ltd. — Investor Relations & Filings

Ticker · 263050 ISIN · KR7263050007 KO Manufacturing
Open in API
Filings indexed 410 across all filing types
Latest filing 2022-08-16 Annual Report
Country KR South Korea
Listing KO 263050

About Eutilex Co.,Ltd.

https://www.eutilex.com/en/

Eutilex Co., Ltd. is a biotechnology company focused on the research and development of immunotherapeutics for cancers and autoimmune diseases. The company's core approach involves selecting targets that enhance or suppress human immune responses. Its pipeline is centered on three primary technology platforms: T-cell therapy, antibody therapy, and CAR-T cell therapy. Key development programs include adoptive T-cell therapies, such as those based on 4-1BB cytotoxic T lymphocytes (CTL), and various immunomodulatory antibody therapeutics designed to treat a range of incurable diseases.

Recent filings

Filing Released Lang Actions
[기재정정]사업보고서 (2021.12)
Annual Report Classification · 100% confidence The document is a 'Business Report' (사업보고서) filed by Eutilex Co., Ltd. It is a formal, comprehensive annual filing submitted to the Financial Supervisory Service (FSS) and the Korea Exchange (KRX). The document contains detailed financial data, management discussions, governance information, and operational updates for the fiscal year 2021. Although it is labeled as a 'correction' (정정신고), it constitutes the full annual report filing required by regulatory authorities, which falls under the 10-K category in the provided schema. FY 2021
2022-08-16 Korean
반기보고서 (2022.06)
Interim / Quarterly Report Classification · 100% confidence The document is a '반기보고서' (Semi-Annual Report) for Eutilex Co., Ltd. for the period ending June 30, 2022. It contains comprehensive financial statements, management discussion and analysis, and corporate governance information, which aligns with the definition of an Interim/Quarterly Report (IR). H1 2022
2022-08-16 Korean
전환사채(해외전환사채포함)발행후만기전사채취득
Capital/Financing Update Classification · 100% confidence The document is a regulatory filing from Eutilex regarding the acquisition of convertible bonds before maturity (early redemption/put option exercise). This falls under capital structure changes and financing updates, specifically related to debt management. According to the provided definitions, 'CAP' (Capital/Financing Update) is the most appropriate category for updates on financing activities and capital structure changes.
2022-08-05 Korean
기타경영사항(자율공시)(항 4-1BB 항체치료제 EU101 러시아 특허권 취득(분할특허))
Regulatory Filings Classification · 100% confidence The document is a voluntary disclosure (자율공시) regarding the acquisition of a patent for a 4-1BB antibody treatment (EU101) in Russia. It does not fit into specific categories like financial reports, board changes, or dividend announcements. As it is a regulatory announcement regarding corporate business developments (patent acquisition) that does not fall into the other specific categories, it is classified as a general regulatory filing.
2022-08-03 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed by Eutilex. This is a standard regulatory filing in South Korea (DART system) used to disclose insider shareholdings and changes in ownership by directors or major shareholders. This falls under the 'Director's Dealing' category as it reports personal share transactions and ownership status of a company director (Kwon Byung-se).
2022-07-29 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a Korean regulatory filing titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). This is a standard disclosure form required by the Financial Supervisory Service (FSS) in South Korea when an insider or major shareholder changes their stake in a company. This falls under the category of 'Director's Dealing' (DIRS) as it reports share ownership changes by a major shareholder (Zhejiang Huahai Pharmaceutical Co., LTD) in the issuer (Eutilex).
2022-07-29 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.